Renaissance Technologies (RenTech)'s LFCR Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 104,859 shares of Lifecore Biomedical, Inc. (LFCR) worth $550,510, representing 0.00% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 45 quarters.
Based on 13F filings since 2013, Renaissance Technologies (RenTech) has maintained a long-term strategic position in LFCR, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2013, adding 135,151 shares. Largest reduction occurred in Q2 2014, reducing 140,696 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Lifecore Biomedical (LFCR) Holding Value Over Time
Track share changes against reported price movement
Quarterly Lifecore Biomedical (LFCR) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +104,859 | New Buy | 104,859 | $5.25 |
| Q3 2024 | -11,000 | Sold Out | 0 | $0.00 |
| Q2 2024 | +11,000 | New Buy | 11,000 | $5.13 |
| Q1 2024 | -36,700 | Sold Out | 0 | $0.00 |
| Q4 2023 | -32,600 | Reduce 47.04% | 36,700 | $6.19 |
| Q3 2023 | -39,951 | Reduce 36.57% | 69,300 | $7.55 |
| Q2 2023 | -62,200 | Reduce 36.28% | 109,251 | $0.01 |
| Q1 2023 | +56,300 | Add 48.89% | 171,451 | $0.00 |
| Q4 2022 | -3,749 | Reduce 3.15% | 115,151 | $0.01 |
| Q3 2022 | -7,900 | Reduce 6.23% | 118,900 | $8.89 |
| Q2 2022 | +8,900 | Add 7.55% | 126,800 | $9.97 |
| Q1 2022 | +1,200 | Add 1.03% | 117,900 | $11.58 |
| Q4 2021 | -4,200 | Reduce 3.47% | 116,700 | $11.10 |
| Q3 2021 | -79,751 | Reduce 39.75% | 120,900 | $9.22 |
| Q2 2021 | -98,000 | Reduce 32.81% | 200,651 | $11.25 |
| Q1 2021 | +94,652 | Add 46.40% | 298,651 | $10.60 |
| Q4 2020 | +92,699 | Add 83.29% | 203,999 | $10.85 |
| Q3 2020 | +10,200 | Add 10.09% | 111,300 | $9.72 |
| Q2 2020 | +82,800 | Add 452.46% | 101,100 | $7.96 |
| Q1 2020 | +18,300 | New Buy | 18,300 | $8.69 |
| Q4 2019 | -41,937 | Sold Out | 0 | $0.00 |
| Q3 2019 | -64,800 | Reduce 60.71% | 41,937 | $10.87 |
| Q2 2019 | -38,900 | Reduce 26.71% | 106,737 | $9.37 |
| Q1 2019 | +10,400 | Add 7.69% | 145,637 | $12.28 |
| Q4 2018 | +28,686 | Add 26.92% | 135,237 | $11.84 |
| Q3 2018 | +86,751 | Add 438.14% | 106,551 | $14.40 |
| Q2 2018 | +19,800 | New Buy | 19,800 | $14.90 |
| Q1 2018 | -15,000 | Sold Out | 0 | $0.00 |
| Q4 2017 | -15,000 | Reduce 50.00% | 15,000 | $12.60 |
| Q3 2017 | +30,000 | New Buy | 30,000 | $12.97 |
| Q1 2017 | -28,082 | Sold Out | 0 | $0.00 |
| Q4 2016 | +28,082 | New Buy | 28,082 | $13.82 |
| Q2 2016 | -20,600 | Sold Out | 0 | $0.00 |
| Q1 2016 | -18,600 | Reduce 47.45% | 20,600 | $10.49 |
| Q4 2015 | +21,200 | Add 117.78% | 39,200 | $11.84 |
| Q3 2015 | +18,000 | New Buy | 18,000 | $11.67 |
| Q2 2015 | -14,100 | Sold Out | 0 | $0.00 |
| Q1 2015 | -4,300 | Reduce 23.37% | 14,100 | $13.97 |
| Q4 2014 | -4,700 | Reduce 20.35% | 18,400 | $13.80 |
| Q3 2014 | -13,000 | Reduce 36.01% | 23,100 | $12.25 |
| Q2 2014 | -140,696 | Reduce 79.58% | 36,100 | $12.49 |
| Q1 2014 | -68,404 | Reduce 27.90% | 176,796 | $11.16 |
| Q4 2013 | -113,551 | Reduce 31.65% | 245,200 | $12.12 |
| Q3 2013 | +135,151 | Add 60.44% | 358,751 | $12.20 |
| Q2 2013 | +223,600 | Add 0.00% | 223,600 | $13.21 |
Renaissance Technologies (RenTech)'s Lifecore Biomedical Investment FAQs
Renaissance Technologies (RenTech) first purchased Lifecore Biomedical, Inc. (LFCR) in Q2 2013, acquiring 223,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Lifecore Biomedical, Inc. (LFCR) for 45 quarters since Q2 2013.
Renaissance Technologies (RenTech)'s largest addition to Lifecore Biomedical, Inc. (LFCR) was in Q2 2013, adding 223,600 shares worth $2.95 M.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 104,859 shares of Lifecore Biomedical, Inc. (LFCR), valued at approximately $550,510.
As of the Q2 2026 filing, Lifecore Biomedical, Inc. (LFCR) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Lifecore Biomedical, Inc. (LFCR) was 358,751 shares, as reported at the end of Q3 2013.